Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Cristina Jercan"'
Autor:
Delia Codruţa Popa, Andreea Şerbănică, Radu Obrisca, Ionut Şerbănică, Letiţia Radu, Cristina Jercan, Andra Marcu, Ana Bica, Minodora Asan, Mădălina Petran, Mihaela Dragomir, Cerasela Jardan, Valeria Ţică, Anca Gheorghe, Irina Stoian, Daniel Coriu, Anca Coliţă, Andrei Coliţă
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancer, with 80–85% represented by B cell ALL and only 15% by T cell ALL. T Cell ALL (T-ALL) carries a more reserved prognosis compared to B Cell ALL (B-ALL) with regard to response
Externí odkaz:
https://doaj.org/article/20273a428980449b87811819bec5c3b1
Autor:
Andreea Şerbănică, Radu Obrişcă, Letiţia Radu, Cristina Jercan, Andra Marcu, Ana-Maria Bică, Petruţa Vasilache, Valentina Pavel, Minodora Asan, Andra Gheorghe, Codruţa Popa, Cerasela Jardan, Constantin Arion, Anca Coliţă
Publikováno v:
Romanian Journal of Medical Practice, Vol 13, Iss 1, Pp 302-311 (2018)
Introduction. Down syndrome (DS) is an important medical problem because it is one of the most frequent genetic diseases in children despite thorough neonatal screening, with an incidence of approximately 1:10 to 1.000 live births worldwide (1,3,4)
Externí odkaz:
https://doaj.org/article/16b2d1f8f5f24cbfb1b17edfd7b9d50c
Autor:
Andreea Şerbănică, Letiţia Radu, Cristina Jercan, Andra Beldiman, Ana Bică, Petruţa Vasilache, Minodora Asan, Oana Grigoraş, Anca Gheorghe, Codruţa Popa, Cerasela Jardan, Constantin Arion, Anca Coliţă
Publikováno v:
Romanian Journal of Pediatrics, Vol 67, Iss 4, Pp 199-205 (2018)
Introducere. Leucemia acută limfoblastică (LAL) este cea mai frecventă formă de cancer în populaţia pediatrică (1). Datorită ajustării continue a protocoalelor terapeutice, rata de supravieţuire a crescut în ultimii ani (2). În ciuda tut
Externí odkaz:
https://doaj.org/article/9d68060fa5374d70a4f05ade7ee07d60
Autor:
Andreea Serbanica, Letitia Radu, Cristina Jercan, Andra Beldiman, Ana Bica, Petruta Vasilache, Minodora Asan, Oana Grigoras, Anca Gheorghe, Codruta Popa, Cerasela Jardan, Constantin Arion, Anca Colita
Publikováno v:
Romanian Journal of Pediatrics, Vol 67, Iss 4, Pp 177-184 (2018)
Introduction. Acute lymphoblastic leukemia (ALL) is the most common form of cancer in the pediatric population (1). The survival rate has increased in recent years due to the continuous adjustment of therapeutic protocols (2). Despite all the efforts
Externí odkaz:
https://doaj.org/article/06ff43d0f41e4253acde1224b1b8e1e8
Autor:
Letitia-Elena Radu, Andrei Colita, Sergiu Pasca, Ciprian Tomuleasa, Codruta Popa, Catalin Serban, Anca Gheorghe, Andreea Serbanica, Cristina Jercan, Andra Marcu, Ana Bica, Patric Teodorescu, Catalin Constantinescu, Bobe Petrushev, Minodora Asan, Cerasela Jardan, Mihaela Dragomir, Alina Tanase, Anca Colita
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Childhood acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the acquisition of several genetic lesions in the lymphoid progenitors with subsequent proliferation advantage and lack of maturation. Along the y
Externí odkaz:
https://doaj.org/article/19bdc832da5d43a380225e67120599af
Autor:
Iustina Grosu, Sabina-Maria Dumitrache, Raluca Stan, Ana Zubaci, Marina Iliescu, Mihaela Tarna, Cristina Jercan, Anca Colita, Cima Luminita Nicoleta, Simona Fica
Publikováno v:
Endocrine Abstracts.
Autor:
Ana Bica, Oana Otilia Niculiță, Pharmacy, Bucharest, Romania, Andra Marcu, Anca Coliță, Cristina Jercan, Roxana Elena Doncu
Publikováno v:
Romanian Journal of Pediatrics, Vol 70, Iss 2, Pp 148-155 (2021)
Introduction. The prognosis of pediatric solid tumors has improved in recent years through the use of multimodal treatment – chemotherapy, local control (surgery and radiotherapy) and hematopoietic stem cell transplantation (HSCT) for high-risk for
Autor:
Andrei Colita, Anca Colita, Alina Tanase, Cristina Jercan, Zsofia Varady, Oana Otilia Niculita, Letitia-Elena Radu
Publikováno v:
Revista de Chimie. 71:195-205
Oral mucositis (OM) is a significant problem in patients undergoing standard or high-dose chemotherapy and/or radiotherapy for the management of haematological disorders, associated with patient morbidity and increased resource use. The OM management
Autor:
Neeraj Saini, Anca Colita, Piyanuch Kongtim, Jin Im, Alina Tanase, Cristina Jercan, Stefan O. Ciurea, Paolo Anderlini, Samer A. Srour, Richard E. Champlin, Fredrick B. Hagemeister, Chitra Hosing, Uday R. Popat, Oana Gabriela Craciun, Ana Bica, Lavinia Lipan, Jeremy Ramdial, Issa F. Khouri, Luis Fayad, Hun J. Lee
Publikováno v:
Bone Marrow Transplantation. 56:278-281
Autor:
Cerasela Jardan, Andra Beldiman, Ana Bica, Andreea Serbanica, Codruta Popa, Anca Colita, Constantin Arion, Anca Gheorghe, Cristina Jercan, Oana Grigoras, Pharmacy, Bucharest, Romania, Minodora Asan, Petruta Vasilache, Letitia Elena Radu
Publikováno v:
Romanian Journal of Pediatrics, Vol 67, Iss 4, Pp 177-184 (2018)
Introduction. Acute lymphoblastic leukemia (ALL) is the most common form of cancer in the pediatric population (1). The survival rate has increased in recent years due to the continuous adjustment of therapeutic protocols (2). Despite all the efforts